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Abstract
Volume therapy is a standard procedure in daily perioperative care, and there is an ongoing
discussion about the benefits of colloid resuscitation with hydroxyethylstarch (HES). In sep-
sis HES should be avoided due to a higher risk for acute kidney injury (AKI). Results of the
usage of HES in patients without sepsis are controversial. Therefore we conducted an ani-
mal study to evaluate the impact of 6% HES 130/0.4 on kidney integrity with sepsis or under
healthy conditions Sepsis was induced by standardized Colon Ascendens Stent Peritonitis
(sCASP). sCASP-group as well as control group (C) remained untreated for 24 h. After 18 h
sCASP+HES group (sCASP+VOL) and control+HES (C+VOL) received 50 ml/KG bal-
anced 6% HES (VOL) 130/0.4 over 6h. After 24h kidney function was measured via Inulin-
and PAH-Clearance in re-anesthetized rats, and serum urea, creatinine (crea), cystatin C
and Neutrophil gelatinase-associated lipocalin (NGAL) as well as histopathology were ana-
lysed. In vitro human proximal tubule cells (PTC) were cultured +/- lipopolysaccharid (LPS)
and with 0.1–4.0% VOL. Cell viability was measured with XTT-, cell toxicity with LDH-test.
sCASP induced severe septic AKI demonstrated divergent results regarding renal function
by clearance or creatinine measure focusing on VOL. Soleley HES (C+VOL) deteriorated
renal function without sCASP. Histopathology revealed significantly derangements in all
HES groups compared to control. In vitro LPS did not worsen the HES induced reduction of
cell viability in PTC cells. For the first time, we demonstrated, that application of 50 ml/KG
6% HES 130/0.4 over 6 hours induced AKI without inflammation in vivo. Severity of sCASP
induced septic AKI might be no longer susceptible to the way of volume expansion.
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Introduction
Infusion therapy is a cornerstone in intensive and perioperative care to increase intravascular
volume and to preserve macro- and microcirculation. In 2008, the VISEP-study results showed
an increased risk of acute kidney injury (AKI) when 10% HES 200/0.4 solution was used in sep-
tic patients[1]. With 6S-, CRYSTMAS- and CHEST-study further trials demonstrated an
increased incidence of AKI, when modern 6% HES 130/0.4 or 0.42 were infused[2–4]. There-
fore the European Medicines Agency´s Pharmacovigilance Risk Assessment Committee
(PRAC) recommended not to use hydroxyethylstarch in sepsis (EMA / 640658 / 2013), despite
of the results of the CRISTAL-study. This study also reveals no differences in AKI using col-
loids (HES, gelatine, dextran or albumin) compared to crystalloids alone[5].
Large amounts of HES are still commonly used in perioperative care. The administration of
starch is based on the widespread belief that this substance improves the treatment for these
patients and therefore reduces morbidity. The pathophysiology of HES-induced AKI is not
fully understood so far. Recently we demonstrated that HES induces decreased cell viability in
human proximal tubules cells (PTC) in vitro (Bruno et al. A&A 2014)[6]. In this trial TNF-α
did not worsen the harmful impact of HES on PTC, but only applied mass of HES molecules
seemed to be responsible for the derogation of human PTC. All investigated HES solutions
(potato or corn derived; balanced or non balanced) and molecular sizes (3–200 kDa) revealed
PTC impairments. Therefore we conducted this study to evaluate, whether inflammation is the
key trigger for HES induced AKI in vivo, or whether HES impairs kidney function even under
healthy conditions in our previously published new rat model of septic AKI [7].
Materials and Methods
Animals
This study was carried out in strict accordance with the recommendation in the Guide for
the Care and Use of Laboratory Animals of the National Institutes of Health. After animal
care committee approval (PM-No. 83/11, Laboratory Animal Care and Use Committee of
the District of Unterfranken, Germany), experiments were performed on 24 male Sprague-
Dawley rats (324±16g bodyweight (BW)) purchased from Harlan Winkelmann (Borchen,
Germany). Animals were treated according to the guidelines of the U.S. National Institutes of
Health, as well as those of Germany. All rats were maintained on a standard diet and water ad
libitum and 12 h day and night cycles. Animals were not fasted prior and after the surgical
interventions.
Animals were randomized to groups I–IV (n = 6/group, Fig 1), group I: Control, group II:
Control+Vol [C+VOL] (balanced 6%HES 130/0.4, Volulyte, Fresenius Kabi, Germany), group
III: sCASP, group IV: sCASP+Vol (balanced 6%HES 130/0.4, Volulyte, Fresenius Kabi, Ger-
many), and anesthetized using isoflurane (Forene, Abbott, Germany) and nitrous oxide inhala-
tion as described previously [7–9]. Briefly the right jugular vein was cannulated for infusion
and medication purposes, and for continuous blood pressure measurement, heart rate (Hewlett
Packard Model 88S) and gaining blood samples, the left carotid artery was also cannulated[9].
sCASP procedure. Animals of group III and IV received the sCASP procedure (for details
see Schick MA et al. 2014 [7]). Spontaneously breathing anesthetized rats were placed in supine
position on a heating pad to ensure normothermia (rectal probe 38±5°C). After thorough dis-
infection of the abdominal skin, a midline incision was performed. The peritoneal cavern was
opened by incising the abdominal muscles and the peritoneum along the linea alba. The cecal
pole was identified and the cecum was gently pulled out by the use of cotton swabs. 20mm dis-
tal from the ileo-cecal valve, the colon was punctured with a 14G needle and to ensure a
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continuous fecal peritonitis in male rats, a 10 FR plastic tube (tip of a suction catheter, type
“Ideal”, B.BraunMelsungen, Germany) was fixed with a suture. Stool was milked from the
cecum towards the colonic stent by the use of cotton swabs until it appeared at the outlet of the
stent. Then the gut was replaced into the peritoneal cavity and the stent was flushed with 2 ml
NaCL 0.9% (Fresenius Kabi, Germany) to distribute the faeces into the peritoneal cavern.
Afterwards the peritoneum and the skin were closed with continuous two layer sutures.
After the surgical procedures, animals woke up and received the following treatments:
Every animal received 14.4 ml/kgBW/24h NaCl 0.9% for basal fluid requirement and after
18 hours C+VOL and sCASP+VOL treated animals received 50 ml/kgBW balanced 6% HES
130/0.4 continuously over the following 6h additionally. All animals had free access to water
and food. Analgesia protocol was performed as follows: Control and C+VOL received 0.25 μg/
100g BW/h fentanyl (Fagron, Germany); CASP and CASP+VOL 2.0 μg/100g BW/h fentanyl
intravenously. Invasive MAP was continuously monitored, and animals would have been
excluded to further investigation if MAP would have dropped below 60 mmHg during the next
24h. However, all animals showed MAP measurements above 60 mmHg for the following
24 hours.
After 24 hours rats were re-anesthetized using Midazolam (Midazolam-ratiopharm, Ratio-
pharm, Germany) 0.7 mg/100g BW/h and Fentanyl 7 μg/100g BW/h. For a sufficient anesthetic
depth, Isofluran was adapted afterwards[10]. Afterwards the animals were weighed again
(322±22g). To establish standardised ventilation, a tracheotomy was performed and rats were
mechanically ventilated with FiO2 0.28% using a Rodent Ventilator (Type: 7025, Hugo Sachs
Elektronic KG, Germany). For cardiac output (CO) measurements the right femoral artery was
cannulated, and a thermocatheter (MLT1402 T-type Ultra Fast Thermocouple, ADInstru-
ments) was introduced to measure CO as previously described [11]. Blood gas values (BGA)
Fig 1. Schematic presentation of the experimental setup. At point of time 0 h after cannulation of the right
jugular vein and the left carotid artery, sham or sCASP procedure was performed. Baseline measurements of
macrohemodynamic and blood gas analysis followed after operation. 18 hours after operation, sCASP+VOL
and Control+VOL received 50 ml/kg/BW 6%HES 130/0.4 (VOL) within the following 6 hours. Twenty-four
hours after first operation, macrohaemodynamics and blood gas parameters were measured, and renal
function was analysed by inulin- and PAH- clearance. At the end of experiment blood serum, blood gas
analysis and kidney were harvested.
doi:10.1371/journal.pone.0137247.g001
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were measured 30 min after the surgical procedure on day one and on day two, 15 min after
the tracheotomy, using ABL505 blood gas analyzer (Radiometer, Copenhagen).
Evaluation of kidney function in vivo. Inulin and PAH clearances were determined as
described recently[12]. In brief, after BGA determination Fluorescein-isothiocyanate-inulin
(Inulin-FITC; F3272–1; Sigma-Aldrich; St. Louis, USA) and PAH (p-Aminohippuric acid
sodium salt; A3759–25G; Sigma-Aldrich; St. Louis, USA) (1 mg of each substance solved in
0.25 ml 0.9% NaCl) were applied (bolus 75μl i.v.), followed by constant infusion of both sub-
stances (2 mg/ml inulin, 5 mg/ml PAH) with a rate of 3.7μl/h/300gBW. The urine bladder was
cannulated with a PE-50 (polyethylene) catheter to measure urine flow and obtain urine sam-
ples. After 30 min of infusion, a steady state was reached. Then urine was collected over a
period of 20 min and blood samples were drawn subsequently. Samples were centrifuged and
stored at −20°C. Inulin concentrations in urine and plasma were determined by fluorescence
spectrometry (1420 Victor2Multilabel Counter), whereas PAH concentrations were measured
by photo spectrometry (Dynatech Lab, Guernsey, UK) using the anthrone method. Calcula-
tions of inulin clearance, PAH clearance, and PNS were performed according to the equations:
inulin clearance = (IU × VU)/(IP × t); PAH clearance = (PAHU × VU)/(PAHP × t); and PNS =
[(PAHU × VU)/t] − [GFR × PAHP]; where IU is inulin concentration in urine; PAHU is PAH
concentration in urine; IP is inulin concentration in plasma; PAHP is PAH concentration in
plasma; VU is urine volume; PNS is PAH net secretion and t is time of measurement.
Markers of acute kidney injury. At the end of experiment plasma samples were drawn for
determination of kidney function and damage by measuring creatinine and urea levels by
using routine laboratory methods. For cystatin C and NGAL, blood samples were collected,
prepared and measured as previously described using rat NGAL (Kit 041 dianova, Germany)
and cystatin C (cystatin c ELISA KIT, AXXORA, Germany) kits[8].
Histopathology. Kidneys were harvested at the end of the experiment for histopatholog-
ical studies. Organ tissues were fixed in formaldehyde 3.5% (Otto Fischar, Germany) for more
than 24 h. Tissues were stained with haematoxylin and eosin reagent and PAS-reaction as pre-
viously described [8, 13]. The morphological alterations of kidneys were analysed semi-quanti-
tatively by a blinded investigator where 0 was given when no alterations were found, 1 for mild
alterations, 2 for medium alterations and 3 for severe alterations. Criteria for histopathological
assessment were formation of oedema, cellular oedema, detachment of tubular epithelium
from the basement membrane, loss of the brush border of the proximal tubular cells, cell death
and vacuolisation. Mean values from the scores of the latter criteria were taken together as total
injury score. Additionally, 10 randomly chosen glomeruli from tissue sections of each group
were selected and distal and proximal tubular cells around the glomeruli were analysed under
high-power fields (6300 magnification) and the score 0 to 4 was given: 0 = none; 1 =< 25%,
2 = 25–50%, 3 = 50–75% and 4 => 75% of the epithelial cells displayed vesicles.
In vitro
For the investigation of the impact of HES in vitro we used our established cell culture of
human proximal tubule cells (HK-2) [6, 14]. In brief HK-2 cells were purchased from ATCC
and used between passage 10 and 29. Cells were cultured in DMEM/HämF12 medium with
10% FCS and 1% penicillin/streptomycin (GIBCO, Invitrogen) for the EZ4U test and without
pyruvat for the LDH tests. For cell viability and cytotoxicity assays 50000 HK-2 cells/cm2 were
seeded on gelatine-coated 96-well plates. Different concentrations of HES were applied onto
HK-2 cells. Cell viability was determined by means of EZ4U assay (second generation tetrazo-
lium dye XTT, Biomedica) after 21 hours substance application according to the manufactur-
er’s instruction. For cytotoxicity (cyt) the Cytotoxicity Detection KIT (LDH-releasing, Roche
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Applied Science Product number 11644793001, Roche Diagnostics GmbH, Mannheim, Ger-
many) was used after 24h according to the manufacturer´s instruction. This assay determines
LDH activity released from damaged cells using the specific absorption of formazan dye mea-
sured with ELISA. Cyt was converted in percent using following equation: cyt = (measured
value-low control)/(high control-low control)x100. High control equals the mean value
obtained from wells with lysed HK-2 cells, while the low control equals to the mean measured
value of HK-2 cells, treated with control solution. Balanced 6% HES130/0.4 solution was
diluted in HK-2 medium to 0.1, 0.5, 1, 1.5, 2, 4% HES using for every dilution the same amount
of HK-2 medium (27.5%). Residual volumes were filled up with NaCl solution (NaCl 0.9, Fre-
senius Kabi Germany). For estimating the influence of pro-inflammatory stimulation, cells
were incubated with different concentrations of lipopolysaccharide (10–100ng/ml LPS from
Escherichia coli 055:B5, purchased from Sigma, Germany). Results were related to control val-
ues from cells treated without HES130/0.4 (= 0% values with HK-2 medium and NaCl only).
0%-control values were set to 100% viability for graphical illustration.
Statistics
Values throughout are expressed as mean ± SEM or SD. In vivo: Statistical analyses were per-
formed using SPSS V. 20 and SPSS V. 21. For parametric parameters possible differences were
assessed with ANOVA followed by post-hoc Duncan test. Statistical significance is assumed for
p< 0.05. For non-parametric data Kruskal-Wallis following Mann-Whitney-U test with Bon-
ferroni correction were used for significant differences. In vitro: For statistical analysis a two-
sided t-test with different variances was used, p-values<0.05 and 0.001 were classified as statis-
tical significant.
Results
In vitro
In our previous studies, HES showed adverse effects on the kidney in sepsis. Therefore we
assessed whether the primarily demonstrated harmful effect of HES is caused by inflammation.
As previously shown for TNF-α [15], we investigated the impact of different dosages of LPS on
cell viability (Fig 2), quantified with the XTT assay. Neither incubation with LPS caused a rele-
vant derangement of cell viability, nor there was a relevant difference between 1.5% HES
(52.66% ± 6.28% SD) and 1.5% HES co-incubated with 100 ng/mLLPS (56.46% ± 5.07%). Fig 2
shows the impact of HES on cell viability after 0h of incubation. The harmful effect of HES can
be determined directly after the administration in vitro. Furthermore, the degree of damage is
very similar to values measured in the later time course [6, 14]. Direct cell toxicity follows belat-
edly this direct decrease of cell viability. While after 4h no relevant increase of cell toxicity incu-
bating with HES was detectable (Fig 2), the values observed after 24h of incubation reveal a
dose depended (beginning with 1.5% HES) statistically significant cell damage (Fig 2: 1.5%
HES: 5,92% ± 5,76% SD, 2% HES: 10,42% ± 5,64% SD and 4% HES: 13,57% ± 8,46% SD).
In vivo—Determination of sepsis induced Acute Kidney Injury
Macrohemodynamics, arterial blood gas parameters and additional plasma analysis are shown
in supplemental materials (S1 Table, S2 Table, S3 Table). All animals treated with sCASP dis-
played clinical features of sepsis, as described previously [7].
Functional Test. First we measured inulin-clearance as the gold standard of global kidney
function (glomerular filtration rate). Administering 6% HES 130/0.4 to rats (C+Vol) resulted
in a significantly reduced inulin-clearance compared to the control animals (0.35±0.25 vs.
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0.72±0.19 [ml/min]) (Fig 3), while the inulin plasma concentrations showed no differences
between the groups (169±28 vs. 171±18 [μl/l]). Additionally PAH-clearance was also signifi-
cantly reduced to 0.84±0.26 [ml/min] in C+Vol when compared to control (3.16±1.53) (Fig 3).
After 24h of sepsis the Inulin-Clearance of sCASP compared to sCASP+Vol showed no signifi-
cant changes between each other as well as compared to control+Vol, but a significant decrease
compared to control (0.20±0.29; 0.22±0.22; 0.35±0.25 vs. 0.72±0.19 [ml/min]) (Fig 3). No sig-
nificant differences were detectable when comparing the inulin plasma concentrations (sCASP
239±79; sCASP+Vol 188±45; C+Vol 169±28; control 171±18 [μl/l]; p-value: 0.389). PAH-
Fig 2. The influence of inflammation, incubation time on the viability and cytotoxicity of human proximal tubule (HK-2) cells. A: Relative reduction of
cell viability by increasing doses of LPS and coincubation of LPS (100 ng /mL) plus 1.5% HES 130/0.4 and 1.5% HES alone, measured after 21 hours. Data
are presented as mean ± SD (n = 36–48), **P < 0.001 versus control, # P < 0.01 vs. each other. B: Relative reduction of cell viability of HK-2 cells by
increasing doses of HES 130/0.4, after 0 hour incubation. Data are presented as mean ± SD (n = 36–48), * vs. control: *P < 0.01, **P < 0.001. C/D: Relative
increase of cytotoxity of HK-2 cells by increasing doses of HES 130/0.4, after 4 (C) and 24 h incubation. Data are presented as mean ± SD (n = 36–48). * vs.
control: **P < 0.001, 2-sided t test with same variances.
doi:10.1371/journal.pone.0137247.g002
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clearance did not reveal any significant variations (Fig 3), while PAH plasma concentrations
showed also no significant differences: Control 78±28, C+Vol 43±7, sCASP 79±40 and sCASP
+Vol 37±11 (μg/ml) (p-value: 0.059).
Urine output. While collecting the urine for the measurement of the Inulin- and PAH--
Clearance, we also measured the amount of urine. Obviously C+Vol, sCASP and sCASP+Vol
showed significantly decreased amounts of urine (0.11±0.03; 0.12±0.10; 0.12±0.13 [ml/20
min]) compared to control (0.36±0.14 [ml/20 min]). When related to body weight these
significances were confirmed: 0.032±0.008, 0.041±0.038; 0.033±0.035 vs. 0.117±0.043 [ml/20
min/100g].
Serummarkers of AKI. The weak standard parameters for AKI, creatinine [mg/dl] and
urea [mg/dl] showed elevated levels, when comparing the two sCASP groups (sCASP, sCASP
+Vol) to control and control+Vol ((88±14; 119±64 vs. 60±11; 63±23) (Fig 3); (0.77±0.14; 0.75
±0.44 vs. 0.35±0.06; 0.44±0.11) (Fig 3)), whereas only creatinine reached significance. Measur-
ing NGAL [pg/ml] revealed significantly increased levels at sCASP and sCASP+Vol animals
compared to control and control+Vol animals ((21±4; 17±6 vs. 7±4; 6±4) (Fig 3)). Fianally
Fig 3. Evaluation of kidney function with serum parameters in vivo after 24 h. A: Inulin-Clearance [ml/
min], the gold standard of kindey function; B: PAH-Clearance [ml/min]; C: NGAL [pg/ml]; D: Cystatin C [pg/
ml]; E: Creatinine [mg/dl] F: Urea [mg/dl], n = 6, * p<0.05 vs. control, # p<0.05 vs. control+Vol. Dotted lines
equal standard values of each parameter.
doi:10.1371/journal.pone.0137247.g003
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cystatin C levels [pg/ml] showed no significant changes, apart from an increase comparing
sCASP+Vol with control ((3721±1572 vs. 1676±105) (Fig 3)).
Histopathology. Infusion of 6% HES 130/0.4 in control animals (C+Vol) had a significant
harmful impact on the kidney shown in the total injury score when compared to control
(4.71±0.12 vs. 2.23±0.11) (Fig 4). Furthermore abdominal sepsis (sCASP, sCASP+Vol)
increased histopathology significantly when compared to control (4.75±0.14; 4.38±0.44 vs.
2.23±0.11) (Fig 4), but there were no significant changes seen between the two groups com-
pared to each other. In the kidneys of the C+Vol group significantly more cellular oedema and
cell death is detectable compared to control. The kidneys of the sCASP group compared to the
sCASP+Vol group, showed significantly more cases of detachment of the basement membrane
of the proximale tubule cells as well as a tendency of more cell deaths and oedema. On the
other hand, sCASP+Vol showed significantly more cellular oedema than sCASP.
Fig 4. Representative images of the renal cortex following PAS reactions (A, B, C, D) and
morphological alterations of the kidney after 24 h (E, F). A/A`: control, B/B`: control+Vol, C/C`: sCASP, D/
D`: sCASP+Vol. Some of the lesion criteria are exemplified. Therefore, magnifications of some areas are
shown (A`, B`, C`, D`). Black arrows showing vacuolization, white big arrows showing detachment of the
basement membrane. White arrowheads showing cells going into cell death. Big black arrows detecting loss
of the brush border of the proximal tubular cells. E: Total Injury Score: Criteria for histopathological
assessment were formation of oedema, cellular oedema, detachment of tubular epithelium from the
basement membrane, loss of the brush border of the proximal tubular cells, cell death and vacuolisation.
Mean values from the scores of the latter criteria were taken together as total injury score. * p<0.05 vs.
control. F: Single criteria of histopathological investigations. * p<0.05 vs. control, § p<0.05 vs. sCASP.
doi:10.1371/journal.pone.0137247.g004
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Discussion
The data of our survey, shows that HES impairs kidney function even under healthy conditions
and inflammation seems not to be the key trigger for HES induced AKI in vivo. Fluid- and vol-
ume resuscitation remains a standard therapy in peri- and postoperative care. The choice of
(invasive-) hemodynamic monitoring, type of solution and amount is an on-going, daily and
controversial discussion[16, 17]. The theoretical advantage of colloid resuscitation with e.g.
hydroxyethylstarch (HES) goes back to Starling’s equation in 1915[18]. In the last decades,
numerous animal and human trials supported Starling’s theory. Because of these results, HES
was the first choice for volume replacement in the OR as well as in the ICU in many countries
for years. The VISEP-study started to show the other side of the story[1]. Further RCTs (6S,
CRYSTMAS and CHEST-study) revealed increased risk for AKI using starch in septic patients
[2–4], however these results were discussed controversially[19]. Parallel to the prohibition of
HES in sepsis (EMA / 640658 / 2013), the validity of Starling´s theory began to falter[20]. It
could be shown, that capillary colloid osmotic pressure gradient in the post-capillary venules
(the theoretical force for fluid re-absorption into the vessels) is not as powerful as predicted by
Starling’s equation[21]. Therefore the theoretical mechanisms about volume improvement
with HES should be reconsidered.
Previously we demonstrated, that colloids (gelatine and HES) revealed histopathological
changes mainly in the renal proximal tubule cells (PTC) in septic rats [8]. Because of reduced
mortality and increased AKI parameters in these animals, we investigated the impact of HES in
human PTCs in vitro. LPS- (Fig 1) as well as TNF-α [6] pretreatment had no influence on the
HES induced reduction of PTC viability. Thus, these inflammatory settings seems not to be
responsible for the harmful impact of colloids on PTC in vitro. Furthermore our results in
vitro showed, that starch origin, molecular size, carrier solution or, older”HES-generation had
marginal influence on the dose depended reduction of PTC viability in vitro [15]. Based on
these results, the pure administrated mass of starch molecules seems to be the key problem for
PTC in vitro. In line with that, a clinical investigation showed, that infusion of more than 33
ml/kgBW synthetical colloids lead to increased risk for AKI in septic patients [22]. Recently, it
has been published, glomerular endothelium is damaged during inflammation which results in
altered glomerular filtration[23]. Therefore HES might be more harmful in sepsis, due to the
breakdown of the filter function in each glomerulum. As a result, more mass of HES molecules
have faster contact to PTC leading to a more rapid incorporation from these kidney brushbor-
der cells. Once HES is incorporated, PTC viability decreased immediately (data not shown)
and cytotoxic HES effects increased over time (Fig 2). In theory, under healthy conditions,
HES molecules< 70 kDa can pass the adult glomerulum and trigger a re-uptake by PTCs.
However filtration barrier of the pediatric glomerulum is not completed and tubular function
matures in the first year of life [24]. Accordingly starch molecules in the primary urine pass to
PTCs and may lead to decreased viability in vivo. This hypothesis may be corroborated by the
meta-analysis about the usage of HES in pediatric patients by Li et al. [25]. They concluded,
that HES might have an adverse effect on renal function. However, in about 1000 children who
received HES during cardiovascular surgery, no increase of AKI was detectable [26]. Witt et al.
used 20 ml/kg HES in a pediatric piglet model and after 7 days, they did not find any relevant
impact on renal function [27].
Therefore, we investigated in this study the impact of HES in sepsis compared to healthy
conditions in our previously established novel animal setup of sCASP. Hereby we are able to
screen macro haemodynamics, kidney function (inulin and PAH clearance) and kidney
derangements (by serum parameters and histopathology) in the same animal [7]. Hypotheti-
cally, HES should be able to impair PTC function even under healthy conditions and sepsis
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should worsen this effect in vivo. In fact, 50 ml/kgBW 6% HES 130/0.4 over 6 h showed harm-
ful side effects in healthy control rats. Interestingly, only inulin-, PAH-clearance, urine output
as well as histopathology showed kidney injury. However, the routine parameters like urea, cre-
atinine, NGAL or cystatin C remained normal. PAH clearance is used as an indirect measure-
ment of renal plasma flow (RPF)[28]. PAH is glomerulary filtered and actively secreted by
PTC. Thus we are not able to distinguish, whether HES reduced RPF or the reduction of PAH
clearance is due to decreased PAH secretion by HES-induced viability reduction in PTC. Inulin
and PAH plasma concentrations, the basis for clearance calculations, depend inter alia on the
total blood volume. Since hematocrit (S2 Table) and total weight showed no differences
between groups, HES treatment did not significantly influence total blood volume. Therefore
individual volume status had no influence on the detected kidney function. Surprisingly, urine
output decreased significantly in healthy rats by 50 ml/kg/BW HES. Therefore, we conclude,
that HES can induce AKI in healthy rats by unknown mechanisms. As expected, HES reduced
renal function in septic animals. Results from in vitro experiments and animal trials are not
directly transferable into the human setting, but allow inspections, which are impossible to get
from clinical human studies. Thus we postulate a diagnostic gap for HES induced AKI in clini-
cal routine, because kidney biopsy in healthy adults for histopathology can/will never be per-
formed in human HES trials.
There remain some possible limitations of this study. We demonstrated in our setup, that
6h of HES treatment reveals derangements of kidney function and morphology in control ani-
mals. However, with our setting, we cannot state a possible reversibility of HES induced AKI
and the threshold of HES in sepsis, shock or other indications for colloids. Additionally our
survey demonstrates that inflammation is no requisite for HES induced AKI. Thus, our
hypothesis of a specific inflammatory driven signal as trigger of the pathomechanism of HES
induced detrimental alterations in septic AKI are not verified.
Conclusion
Despite of renal replacement therapy and improved intensive- and perioperative care medicine,
development of AKI increases mortality and morbidity. There is growing evidence, that starch
molecules induce AKI by unknown pathways. For the first time we demonstrated, that 50 ml/
kgBW 6% HES 130/0.4 induced AKI within 6h in healthy rats. To proof the statement, that
applying HES for volume resuscitation improves outcome, additional clinical trials and studies,
focusing on adverse effects of HES regarding kidney function, are needed.
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